Prof. Dr. med. Axel Stuart Merseburger is a highly experienced urologist with over 21 years of practice. He works at the Department of Urology at the University Hospital Schleswig-Holstein in Lubeck, Germany and specializes in urology and robotic surgery. Dr Merseburger is considered an expert in his field with a wide range of qualifications and achievements. Having studied medicine at top institutions such as the Hannover Medical School and the Harvard Medical School, Dr Merseburger has gained extensive knowledge and expertise. He has completed various fellowships and training, including a scholarship at the Uniformed Services University in Washington and a fellowship at the Henry M Jackson Foundation Center for Prostate Disease Research. Dr Merseburger has published 442 scientific publications, demonstrating his dedication to research and innovation. He has received numerous awards and prizes, including the Werner Staehler Memorial and Urologia Internationalis prizes. With his wealth of experience and expertise, Dr Merseburger is known for his contributions to the field of urology. He is highly regarded for his skills in robotic surgery and his focus on prostate cancer. His dedication to improving patient outcomes and advancing the field of urology makes him a highly respected and trusted doctor. Overall, Prof. Dr. med. Axel Stuart Merseburger is an accomplished urologist who brings knowledge and expertise to his practice. His dedication to research, innovative treatments and patient care makes him a valuable asset to the medical community.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen.  She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others.  She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007.

Domenica Lorusso, MD, PhD, is Director of Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano, Milan. Prof. Lorusso has been involved in gynecological oncology research for more than 25 years and has conducted or participated in approximately 250 phase I-IV clinical trials in gynecological malignancies. At present she is Principal Investigators of more than 60 studies.

Prof. Lorusso is responsible for the Clinical Trials Committee of the MITO (Multicenter Italian Trials in Ovarian Cancer and Gynaecological Malignancies) Group, which includes more than 150 Italian centers involved in gynecological oncology research. She is a member of the Board of Directors of Gynaecological Cancer Intergroup including 23 international research groups involved in the promotion and conduction of high-quality clinical trials to improve outcomes for women with gynecological cancers. Prof. Lorusso is also an active member of ENGOT (European Network of Gynaecological Oncological Trial groups), an international organization which coordinates and promotes clinical trials within Europe for patients with gynecological cancers where she chairs the Gynecological Cancer Academy. She is a member of the Board of Director of the European Society of Gynecological Oncology (ESGO). She has also co-authored about 300 international oncology publications. She is author of national and international guidelines on treatment of ovarian, cervical and endometrial cancer.

Prof. Lorusso’s key goals are to ensure best treatment to all patients and promote the clinical research, international trial collaborations and educations.

Dr Aapro coordinates the Sharing Progress in Cancer Care (SPCC) program of the European School of Oncology (ESO) and serves the International Society for Geriatric Oncology (SIOG) as an Executive Board member. He has been a member of the board of the European Organization for Research and Treatment of Cancer (EORTC) and of the European Society of Medical Oncology (ESMO). He is Past President of the Multinational Association for Supportive Care in Cancer (MASCC), and is now on its Board of Directors for 2012 to 2014.

Dr Aapro is Editor-in-Chief of Critical Reviews in Oncology/Hematology, Associate Editor for the geriatric section of the Oncologist, and is Founding Editor of the Journal of Geriatric Oncology, and was Associate Editor for Annals of Oncology. He has authored more than 250 publications and his major interests are new drug development, breast cancer, supportive care, and cancer in the elderly.

Dr Aapro received the 2012 ASCO BJ Kennedy prize.